JP5991974B2 - 新規アミノピラゾロキナゾリン - Google Patents
新規アミノピラゾロキナゾリン Download PDFInfo
- Publication number
- JP5991974B2 JP5991974B2 JP2013520164A JP2013520164A JP5991974B2 JP 5991974 B2 JP5991974 B2 JP 5991974B2 JP 2013520164 A JP2013520164 A JP 2013520164A JP 2013520164 A JP2013520164 A JP 2013520164A JP 5991974 B2 JP5991974 B2 JP 5991974B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- cycloalkyl
- compound according
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- GSPJKQDGNFCKSS-UHFFFAOYSA-N CCC1=CN(C)NN1 Chemical compound CCC1=CN(C)NN1 GSPJKQDGNFCKSS-UHFFFAOYSA-N 0.000 description 1
- 0 C[C@]1c2cnc(**)nc2-c2c(C)[n](*)nc2CC1 Chemical compound C[C@]1c2cnc(**)nc2-c2c(C)[n](*)nc2CC1 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N c1ccccc1 Chemical compound c1ccccc1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N c1ccncc1 Chemical compound c1ccncc1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10170683.6 | 2010-07-23 | ||
| EP10170683 | 2010-07-23 | ||
| PCT/EP2011/062683 WO2012010704A1 (en) | 2010-07-23 | 2011-07-22 | New aminopyrazoloquinazolines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013532652A JP2013532652A (ja) | 2013-08-19 |
| JP2013532652A5 JP2013532652A5 (enExample) | 2015-09-03 |
| JP5991974B2 true JP5991974B2 (ja) | 2016-09-14 |
Family
ID=43037625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013520164A Active JP5991974B2 (ja) | 2010-07-23 | 2011-07-22 | 新規アミノピラゾロキナゾリン |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8735386B2 (enExample) |
| EP (1) | EP2595987B1 (enExample) |
| JP (1) | JP5991974B2 (enExample) |
| KR (1) | KR20130132394A (enExample) |
| CN (1) | CN103097388A (enExample) |
| AP (1) | AP2012006640A0 (enExample) |
| AR (1) | AR082850A1 (enExample) |
| AU (1) | AU2011281504A1 (enExample) |
| BR (1) | BR112013000107A2 (enExample) |
| CA (1) | CA2803467A1 (enExample) |
| CL (1) | CL2012003745A1 (enExample) |
| CO (1) | CO6670575A2 (enExample) |
| EA (1) | EA201201661A1 (enExample) |
| EC (1) | ECSP13012448A (enExample) |
| GE (1) | GEP20156289B (enExample) |
| MA (1) | MA34389B1 (enExample) |
| MX (1) | MX2013000821A (enExample) |
| PE (1) | PE20131143A1 (enExample) |
| PH (1) | PH12013500152A1 (enExample) |
| SG (1) | SG187548A1 (enExample) |
| TW (1) | TW201217380A (enExample) |
| UY (1) | UY33526A (enExample) |
| WO (1) | WO2012010704A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201343648A (zh) * | 2012-01-23 | 2013-11-01 | Boehringer Ingelheim Int | 作為ｉｇｆ－１ｒ／ｉｒ抑制劑之新５，８－二氫－６ｈ－吡唑并［３，４－ｈ］喹唑啉 |
| US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| PT3068401T (pt) * | 2013-11-15 | 2019-06-04 | Oncoceutics Inc | 7-benzil-4-(2-metilbenzil)-2,4,6,7,7,8,9-hexaidroimidazo[1,2- a]pirido[3,4-e]pirimidin-5(1h)-ona, seus sais e métodos de uso |
| PT3805222T (pt) | 2015-01-30 | 2025-03-10 | Oncoceutics Inc | Derivados de 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-hexa-hidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, seus sais e sua utilização em terapia |
| US10414769B2 (en) | 2015-05-13 | 2019-09-17 | Boehringer Ingelheim International Gmbh | 5,8-dimethyl-9-phenyl-5,8-dihydro-6H-pyrazolo[3,4-h]quinazolin-2-yl)-(1H-pyrazol-3-yl)-amines as IGF-1R/IR inhibitors |
| JP6905069B2 (ja) * | 2016-11-11 | 2021-07-21 | 上海海雁醫藥科技有限公司 | ピリジルアミノ置換へテロ三環式化合物並びにその製造方法及び医薬用途 |
| DK3632904T3 (da) * | 2017-05-26 | 2022-07-25 | Jiangsu Atom Bioscience And Pharmaceutical Co Ltd | URAT1-inhibitorer til at fremme urinsyreudskillelse |
| CN107383019B (zh) * | 2017-07-28 | 2019-10-15 | 江苏艾凡生物医药有限公司 | 吡唑并[4,3-h]喹唑啉类化合物及其用途 |
| WO2019206154A1 (zh) | 2018-04-24 | 2019-10-31 | 上海海雁医药科技有限公司 | Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| EP3873431A1 (en) | 2018-11-02 | 2021-09-08 | Fount Bio, Inc. | Crosslinked materials |
| US20220098214A1 (en) * | 2019-01-30 | 2022-03-31 | Yale University | Compounds, compositions, and methods for treating fibrosis |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| US20220144822A1 (en) * | 2019-03-07 | 2022-05-12 | BioNTech SE | Process for the preparation of a substituted imidazoquinoline |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| JP7650817B2 (ja) * | 2019-04-19 | 2025-03-25 | ファウント バイオ， インコーポレイテッド | 皮膚内への活性剤の送達および保持 |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| AU2020328025A1 (en) | 2019-08-14 | 2022-03-03 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| JOP20220087A1 (ar) | 2019-10-11 | 2023-01-30 | Incyte Corp | أمينات ثنائية الحلقة كمثبطات لـ cdk2 |
| IL298760A (en) | 2020-06-05 | 2023-02-01 | Kinnate Biopharma Inc | Fibroblast growth factor receptor kinase inhibitors |
| CN111960974A (zh) * | 2020-08-28 | 2020-11-20 | 山东潍坊润丰化工股份有限公司 | 一种烯草酮中间体的合成方法 |
| WO2022166725A1 (zh) * | 2021-02-08 | 2022-08-11 | 南京明德新药研发有限公司 | 5，6-二氢噻吩并[3，4-h]喹唑啉类化合物 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE222892T1 (de) * | 1995-10-02 | 2002-09-15 | Hoffmann La Roche | Pyrimidinderivate als 5ht2c-rezeptorantagonisten |
| BRPI0410563B8 (pt) | 2003-05-22 | 2021-05-25 | Nerviano Medical Sciences Srl | compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas |
| CN1897950A (zh) * | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
-
2011
- 2011-07-20 US US13/187,100 patent/US8735386B2/en active Active
- 2011-07-21 UY UY0001033526A patent/UY33526A/es not_active Application Discontinuation
- 2011-07-22 AU AU2011281504A patent/AU2011281504A1/en not_active Abandoned
- 2011-07-22 MX MX2013000821A patent/MX2013000821A/es active IP Right Grant
- 2011-07-22 WO PCT/EP2011/062683 patent/WO2012010704A1/en not_active Ceased
- 2011-07-22 PH PH1/2013/500152A patent/PH12013500152A1/en unknown
- 2011-07-22 KR KR1020137003430A patent/KR20130132394A/ko not_active Withdrawn
- 2011-07-22 AP AP2012006640A patent/AP2012006640A0/xx unknown
- 2011-07-22 EA EA201201661A patent/EA201201661A1/ru unknown
- 2011-07-22 EP EP11734158.6A patent/EP2595987B1/en active Active
- 2011-07-22 AR ARP110102670A patent/AR082850A1/es unknown
- 2011-07-22 JP JP2013520164A patent/JP5991974B2/ja active Active
- 2011-07-22 GE GEAP201113008A patent/GEP20156289B/en unknown
- 2011-07-22 PE PE2013000125A patent/PE20131143A1/es not_active Application Discontinuation
- 2011-07-22 CN CN201180043930XA patent/CN103097388A/zh active Pending
- 2011-07-22 MA MA35577A patent/MA34389B1/fr unknown
- 2011-07-22 BR BR112013000107A patent/BR112013000107A2/pt not_active IP Right Cessation
- 2011-07-22 CA CA2803467A patent/CA2803467A1/en not_active Abandoned
- 2011-07-22 SG SG2013003645A patent/SG187548A1/en unknown
- 2011-07-22 TW TW100126062A patent/TW201217380A/zh unknown
-
2012
- 2012-12-28 CL CL2012003745A patent/CL2012003745A1/es unknown
-
2013
- 2013-01-22 CO CO13011464A patent/CO6670575A2/es active IP Right Grant
- 2013-02-19 EC ECSP13012448 patent/ECSP13012448A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201217380A (en) | 2012-05-01 |
| EA201201661A1 (ru) | 2013-07-30 |
| WO2012010704A1 (en) | 2012-01-26 |
| MA34389B1 (fr) | 2013-07-03 |
| UY33526A (es) | 2012-02-29 |
| AU2011281504A1 (en) | 2013-01-10 |
| US20120238542A1 (en) | 2012-09-20 |
| BR112013000107A2 (pt) | 2016-05-17 |
| AR082850A1 (es) | 2013-01-16 |
| KR20130132394A (ko) | 2013-12-04 |
| EP2595987A1 (en) | 2013-05-29 |
| JP2013532652A (ja) | 2013-08-19 |
| CA2803467A1 (en) | 2012-01-26 |
| PH12013500152A1 (en) | 2013-02-18 |
| CO6670575A2 (es) | 2013-05-15 |
| MX2013000821A (es) | 2013-05-30 |
| CL2012003745A1 (es) | 2013-05-31 |
| SG187548A1 (en) | 2013-03-28 |
| AP2012006640A0 (en) | 2012-12-31 |
| ECSP13012448A (es) | 2013-03-28 |
| EP2595987B1 (en) | 2018-04-18 |
| GEP20156289B (en) | 2015-05-25 |
| US8735386B2 (en) | 2014-05-27 |
| PE20131143A1 (es) | 2013-10-23 |
| CN103097388A (zh) | 2013-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5991974B2 (ja) | 新規アミノピラゾロキナゾリン | |
| JP5809288B2 (ja) | Ｉｇｆ１ｒ受容体阻害薬としてのオキシインドールピリミジン | |
| JP5871896B2 (ja) | Ｂ−ｒａｆキナーゼインヒビター | |
| JP5863058B2 (ja) | １Ｈ−イミダゾ［４，５−ｃ］キノリン | |
| JP6128133B2 (ja) | Ｉｇｆ−１ｒ／ｉｒ阻害剤としての５，８−ジヒドロ−６ｈ−ピラゾロ［３，４−ｈ］キナゾリン | |
| JP5871897B2 (ja) | ピリジルトリアゾール | |
| JP5959754B2 (ja) | トリアゾロピラジン | |
| JP6370368B2 (ja) | Ｂｒｄ４阻害剤としてのインドリノン類似体 | |
| JP5850952B2 (ja) | セリン／スレオニンキナーゼ阻害剤としての新しいアザインドリルフェニルスルホンアミド | |
| JP6453845B2 (ja) | Ｂｒｄ４阻害薬としてのジヒドロキナゾリノン類似体 | |
| JP6370376B2 (ja) | Ｂｒｄ４阻害薬としてのトリアゾロピラジン誘導体 | |
| JP5860031B2 (ja) | Ｐｄｋ１阻害薬としてのヘテロ環式カルボン酸アミド | |
| JP5824068B2 (ja) | セリン／トレオニンキナーゼ阻害剤としての新規トリアゾリルフェニルスルホンアミド | |
| JP6085873B2 (ja) | トリアゾロピリダジン | |
| JP6488367B2 (ja) | ベンゾイミダゾール誘導体 | |
| JP2014503573A (ja) | セリン／スレオニンキナーゼ阻害薬としての新規ピリミド［５，４−ｄ］ピリミジルアミノフェニルスルホンアミド | |
| HK1180313A (en) | New aminopyrazoloquinazolines | |
| TW201307321A (zh) | 新苯甲基羥吲哚嘧啶 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140709 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140709 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150416 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150430 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20150713 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160531 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20160613 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160719 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160816 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5991974 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |